Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.34 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CDK11B | P21127 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.33 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.33 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.33 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841877 | 0.90 | TERT (0.40) | AKT1TSHRCYP3A4SLC1A2SMN1; SMN2 | |
| SCHEMBL30269173 | 0.90 | TERT (0.40) | AKT1TSHRCYP3A4SLC1A2SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL27959221 | 0.80 | ALDH1A1 (0.35) | AKT1NPY1R | |
| SCHEMBL16652232 | 0.76 | TSHR (0.44) | AKT1TSHRCYP3A4SLC1A2SMN1; SMN2 | |
| SCHEMBL12107712 | 0.76 | SLC1A2 (0.40) | TSHRSLC1A2SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL20677165 | 0.75 | TACR1 (0.32) | AKT1TACR1TACR3TERT | |
| SCHEMBL18877419 | 0.74 | SMN1; SMN2 (0.41) | TSHRSLC1A2SMN1; SMN2HTT | |
| Trifluoroacetic Acid SCHEMBL18261651 | 0.73 | PKM (0.38) | AKT1SMN1; SMN2ESR1ESR2CSNK1D | |
| SCHEMBL10037527 | 0.73 | CPB2 (0.34) | SLC1A2TERT | |
| SCHEMBL10037495 | 0.73 | SLC1A2 (0.42) | TSHRSLC1A2SMN1; SMN2HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | KIF23, KIF2C, KIF18A | AKT1 3824/4885TSHR 3684/4885CYP3A4 4715/4885 |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | KIF5B, KIF23, KIF2C | AKT1 2463/4885TSHR 4052/4885CYP3A4 4711/4885 |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | AKT1 3148/4885TSHR 4473/4885CYP3A4 4637/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | AKT1 2957/4885TSHR 3868/4885CYP3A4 4771/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | AKT1 4093/4885TSHR 2038/4885CYP3A4 4541/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | AKT1 3148/4885TSHR 4473/4885CYP3A4 4637/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | AKT1 2463/4885TSHR 4052/4885CYP3A4 4711/4885 |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | KIF23, KIF2C, KIF18A | AKT1 3824/4885TSHR 3684/4885CYP3A4 4715/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | AKT1 2462/4885TSHR 4525/4885CYP3A4 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.